Ketema Tasisa, Tadele Markos, Gebrie Zewdie, Makonnen Eyasu, Hailu Asrat, Abay Solomon M
Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia.
Animal Health Research Program, Ethiopian Institute of Agricultural Research, Holetta, Ethiopia.
J Exp Pharmacol. 2023 Mar 13;15:123-135. doi: 10.2147/JEP.S397352. eCollection 2023.
INTRODUCTION: Leishmaniasis is one of the neglected tropical diseases, threatening lives of about 350 million people globally. seeds are used for the treatment of cutaneous leishmaniasis in the traditional medicine in Ethiopia. OBJECTIVE: This study aimed to evaluate seeds' anti-leishmanial activity in vitro. METHODS: The crude (80% methanol) extract of seeds and its fractions were evaluated for their anti-leishmanial activities against promastigotes and intracellular amastigotes of , and for their cytotoxic effects against mammalian cells. The quantitative estimations of total phenolic compounds (TPCs), flavonoids (TFCs) and alkaloids (TACs) were determined, spectrophotometrically. Median inhibitory concentration (IC) and median cytotoxic concentration (CC) of the extract and its solvent fractions were calculated using GraphPad Prism 9.1.0 computer software. Data was presented as mean ± standard error of the mean (SEM). RESULTS: The crude extract and its hexane, ethyl acetate and butanol fractions showed anti-leishmanial activities, with IC values of 4.14-60.12 µg/mL against promastigotes, and 6.16-40.12 µg/mL against amastigotes of both species. They showed moderate cytotoxicity against Vero cell lines and peritoneal mice macrophages, with CC values of 100-500 µg/mL, but >1600 µg/mL against red blood cells. Selectivity indices ranged from 7.97 to 30.97. The crude extract, and its ethyl acetate and hexane fractions possessed 54.78-127.72 mg of gallic acid equivalent TPC, 18.30-79.21 mg of quercetin equivalent TFC, and 27.62-97.22 mg of atropine equivalent TAC per gram of extracts. CONCLUSION: The seeds of the plant possessed anti-leishmanial activities against and that might provide a scientific justification for its use in the treatment of leishmaniasis by traditional healers. Future works are recommended to isolate, purify and identify the possible secondary metabolites attributed to the anti-leishmanial activity.
J Exp Pharmacol. 2023-3-13
BMC Complement Med Ther. 2021-3-31
J Exp Pharmacol. 2021-1-15
Front Chem. 2025-4-1
Front Pharmacol. 2021-7-20
J Exp Pharmacol. 2021-1-15
Profiles Drug Subst Excip Relat Methodol. 2021
Evid Based Complement Alternat Med. 2020-4-21
Drug Des Devel Ther. 2020
Molecules. 2019-12-3
PLoS Negl Trop Dis. 2019-5-9
PLoS Negl Trop Dis. 2019-5-2